Email this article 
GLUCOSAMINYLMURAMYL DIPEPTIDE IN THE THERAPY OF PATIENTS WITH ATOPIC BRONCHIAL ASTHMA AND CLINICAL MANIFESTATIONS OF THE SYNDROME OF SECONDARY IMMUNE DEFICIENCY
- Authors: Skorokhodkina OV1, Luntsov AV2
-
Affiliations:
- Kazan State Medical University
- Republican Clinical Hospital
- Issue: Vol 14, No 6 (2017)
- Pages: 91-97
- Section: Articles
- URL: https://rusalljournal.ru/raj/article/view/286
- DOI: https://doi.org/10.36691/RJA286
- ID: 286
Cite item
Open Access
Access granted
Abstract
Background. Glucosaminylmuramyl dipeptide (likopid) is a selective NOD2 receptor agonist, its ability to activate phagocytes proves its use in infectious manifestations in asthma patients. Its influence on the adaptive immunity, was studied. The aim of the study was to evaluate the effectiveness of likopid in patients with atopic bronchial asthma and recurrent infections of the respiratory tract. Materials and methods. 44 patients with uncontrolled atopic bronchial asthma with recurrent respiratory tract infections were examined. Patients of group I received likopid 10 mg orally once a day during 10 days additionally to the complex therapy. Patients of group II received only complex therapy without likopid. The immune parameters, disease control parameters, frequency of exacerbations and spirography data in patients of two groups before the treatment and after 10 days, 1 and 3 months were assessed. Results. Both I and II group patients (91,6%) showed similar deviations of the immune status parameters in general, a depression of the functional activity of phagocytes was noted in 83,3% of cases. Patients of group I were characterized by the achievement of better asthma control in 1 month of treatment, while the frequency of asthma exacerbations required revision of therapy was lower in patients of group I than in patients of group II (8,3% and 45%, respectively, p<0,001). The patients of group I, receiving likopid, had increased phagocytic activity after 10 days of treatment, while significant changes were recorded after 1 month of treatment; a decrease in these parameters was shown only in 45,8% (p<0,001) of patients in 3 months of treatment. The conclusion. The use of glucosaminylmuramyl dipeptide in atopic bronchial asthma accompanied with clinical manifestations of the secondary immune deficiency leads to correction of phagocytic activity, as well as to significant decreasing of infections incidence and improving of bronchial asthma symptoms control.
Full Text
About the authors
O V Skorokhodkina
Kazan State Medical University
Email: olesya-27@rambler.ru
49, Butlerov str., Kazan, 420012, Russia
A V Luntsov
Republican Clinical Hospital138, Orenburgsky tract, Kazan, 420064, Russia
References
- Сизякина ЛП, Чурюкина ЭВ. Клинико-иммунологическая характеристика фенотипа бронхиальной астмы с синдромом вторичной иммунной недостаточности. Российский Аллергологический Журнал. 2015; (2): 10-14.
- Хаитов РМ, Ильина НИ. Аллергология и иммунология. Национальное руководство. М., «ГЭОТАР-Медиа». 2012: 649.
- Несмеянов ВА. Глюкозаминилмурамилпептиды: на пути к пониманию молекулярного механизма биологической активности. International Journal of Immunorehabilitation. 1998; (10): 19-29.
- Караулов АВ, Калюжин ОВ. Иммунотерапия инфекционных болезней: проблемы и перспективы. Терапевтический архив. 2013; (11): 100-108.
- Колесникова НВ, Коков ЕА, Кокова ЛН, Чудилова ГА, Нехотина ИВ. Экспериментальная оценка механизмов IgE-супрессирующих эффектов мурамилдипептидов. Кубанский научный медицинский вестник. 2010; (1): 48-51
- Козлов ИГ, Гурьянова СВ, Колесникова НВ, Андронова ТМ. Мурамилдипептиды и другие агонисты рецепторов врожденного иммунитета в комплексной терапии аллергических заболеваний. Российский Аллергологический Журнал. 2015; (5): 59-67.
- Wong CK, Hu S, Leung KM, Dong J, He L, Chu YJ et al. NOD-like receptors mediated activation of eosinophils interacting with bronchial epithelial cells: a link between innate immunity and allergic asthma. Cell Mol Immunol. 2013; 10(4): 317-329.
- Duan W, Mehta AK, Magalhaes JG, Ziegler SF, Dong C, Philpott DJ et al. Innate signals from NOD2 block respiratory tolerance and program T(H)2-driven allergic inflammation. J Allergy Clin Immunol. 2010; 126(6): 1284-1293.
- Kvarnhammar AM, Petterson T, Cardell LO. NOD-like receptors and RIG-I-like receptors in human eosinophils: activation by NOD1 and NOD2 agonists. Immunology. 2011; 134(3): 314-325.
- Лусс ЛВ. Вторичная иммунная недостаточность и имму-нокомпрометированный пациент. Аллергология и иммунология в педиатрии. 2007; (2): 6-11.
Supplementary files
